These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 34886943)
1. Neutralisation of the SARS-CoV-2 Delta variant sub-lineages AY.4.2 and B.1.617.2 with the mutation E484K by Comirnaty (BNT162b2 mRNA) vaccine-elicited sera, Denmark, 1 to 26 November 2021. Lassaunière R; Polacek C; Fonager J; Bennedbæk M; Boding L; Rasmussen M; Fomsgaard A Euro Surveill; 2021 Dec; 26(49):. PubMed ID: 34886943 [TBL] [Abstract][Full Text] [Related]
2. The effect of the E484K mutation of SARS-CoV-2 on the neutralizing activity of antibodies from BNT162b2 vaccinated individuals. Uwamino Y; Yokoyama T; Shimura T; Nishimura T; Sato Y; Wakui M; Kosaki K; Hasegawa N; Murata M Vaccine; 2022 Mar; 40(13):1928-1931. PubMed ID: 35183387 [TBL] [Abstract][Full Text] [Related]
3. Neutralising capacity against Delta (B.1.617.2) and other variants of concern following Comirnaty (BNT162b2, BioNTech/Pfizer) vaccination in health care workers, Israel. Lustig Y; Zuckerman N; Nemet I; Atari N; Kliker L; Regev-Yochay G; Sapir E; Mor O; Alroy-Preis S; Mendelson E; Mandelboim M Euro Surveill; 2021 Jul; 26(26):. PubMed ID: 34212838 [TBL] [Abstract][Full Text] [Related]
4. Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera. Xie X; Liu Y; Liu J; Zhang X; Zou J; Fontes-Garfias CR; Xia H; Swanson KA; Cutler M; Cooper D; Menachery VD; Weaver SC; Dormitzer PR; Shi PY Nat Med; 2021 Apr; 27(4):620-621. PubMed ID: 33558724 [TBL] [Abstract][Full Text] [Related]
5. The SARS-CoV-2 Lambda variant and its neutralisation efficiency following vaccination with Comirnaty, Israel, April to June 2021. Zuckerman N; Nemet I; Kliker L; Atari N; Lustig Y; Bucris E; Bar Ilan D; Geva M; Sorek-Abramovich R; Weiner C; Rainy N; Bar-Chaim A; Benveniste-Levkovitz P; Abu Hamed R; Regev-Yochay G; Hevkin O; Mor O; Alroy-Preis S; Mendelson E; Mandelboim M Euro Surveill; 2021 Nov; 26(45):. PubMed ID: 34763751 [TBL] [Abstract][Full Text] [Related]
6. Fusogenicity and neutralization sensitivity of the SARS-CoV-2 Delta sublineage AY.4.2. Saunders N; Planas D; Bolland WH; Rodriguez C; Fourati S; Buchrieser J; Planchais C; Prot M; Staropoli I; Guivel-Benhassine F; Porrot F; Veyer D; Péré H; Robillard N; Saliba M; Baidaliuk A; Seve A; Hocqueloux L; Prazuck T; Rey FA; Mouquet H; Simon-Lorière E; Bruel T; Pawlotsky JM; Schwartz O EBioMedicine; 2022 Mar; 77():103934. PubMed ID: 35290827 [TBL] [Abstract][Full Text] [Related]
7. SARS-CoV-2 lineage dynamics in England from September to November 2021: high diversity of Delta sub-lineages and increased transmissibility of AY.4.2. Eales O; Page AJ; de Oliveira Martins L; Wang H; Bodinier B; Haw D; Jonnerby J; Atchison C; ; Ashby D; Barclay W; Taylor G; Cooke G; Ward H; Darzi A; Riley S; Chadeau-Hyam M; Donnelly CA; Elliott P BMC Infect Dis; 2022 Jul; 22(1):647. PubMed ID: 35896970 [TBL] [Abstract][Full Text] [Related]
8. Comparable neutralization of SARS-CoV-2 Delta AY.1 and Delta with individuals sera vaccinated with BBV152. Yadav PD; Sahay RR; Sapkal G; Nyayanit D; Shete AM; Deshpande G; Patil DY; Gupta N; Kumar S; Abraham P; Panda S; Bhargava B J Travel Med; 2021 Dec; 28(8):. PubMed ID: 34581415 [TBL] [Abstract][Full Text] [Related]
10. BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar. Tang P; Hasan MR; Chemaitelly H; Yassine HM; Benslimane FM; Al Khatib HA; AlMukdad S; Coyle P; Ayoub HH; Al Kanaani Z; Al Kuwari E; Jeremijenko A; Kaleeckal AH; Latif AN; Shaik RM; Abdul Rahim HF; Nasrallah GK; Al Kuwari MG; Al Romaihi HE; Butt AA; Al-Thani MH; Al Khal A; Bertollini R; Abu-Raddad LJ Nat Med; 2021 Dec; 27(12):2136-2143. PubMed ID: 34728831 [TBL] [Abstract][Full Text] [Related]
11. Early Emergence and Dispersal of Delta SARS-CoV-2 Lineage AY.99.2 in Brazil. Romano CM; de Oliveira CM; da Silva LS; Levi JE Front Med (Lausanne); 2022; 9():930380. PubMed ID: 35783651 [TBL] [Abstract][Full Text] [Related]
12. BNT162b2-elicited neutralization of Delta plus, Lambda, Mu, B.1.1.519, and Theta SARS-CoV-2 variants. Liu J; Liu Y; Xia H; Zou J; Weaver SC; Swanson KA; Cai H; Cutler M; Cooper D; Muik A; Jansen KU; Sahin U; Xie X; Dormitzer PR; Shi PY NPJ Vaccines; 2022 Apr; 7(1):41. PubMed ID: 35396516 [TBL] [Abstract][Full Text] [Related]
13. Dynamics of Antibody Response to BNT162b2 mRNA COVID-19 Vaccine: A 7-Month Follow-Up Study. Olariu TR; Ursoniu S; Marincu I; Lupu MA Medicina (Kaunas); 2021 Dec; 57(12):. PubMed ID: 34946275 [No Abstract] [Full Text] [Related]
14. Serosurvey in BNT162b2 vaccine-elicited neutralizing antibodies against authentic B.1, B.1.1.7, B.1.351, B.1.525 and P.1 SARS-CoV-2 variants. Zani A; Caccuri F; Messali S; Bonfanti C; Caruso A Emerg Microbes Infect; 2021 Dec; 10(1):1241-1243. PubMed ID: 34092181 [TBL] [Abstract][Full Text] [Related]
15. Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera. Muik A; Wallisch AK; Sänger B; Swanson KA; Mühl J; Chen W; Cai H; Maurus D; Sarkar R; Türeci Ö; Dormitzer PR; Şahin U Science; 2021 Mar; 371(6534):1152-1153. PubMed ID: 33514629 [TBL] [Abstract][Full Text] [Related]